These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5965 related articles for article (PubMed ID: 2805780)

  • 1. Generation of autologous tumor-specific cytotoxic T-cells using HLA-A region matched allogeneic melanoma.
    Crowley NJ; Darrow TL; Seigler HF
    Curr Surg; 1989; 46(5):393-6. PubMed ID: 2805780
    [No Abstract]   [Full Text] [Related]  

  • 2. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.
    de Vries JE; Spits H
    J Immunol; 1984 Jan; 132(1):510-9. PubMed ID: 6197458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells.
    Zennadi R; Abdel-Wahab Z; Seigler HF; Darrow TL
    Cell Immunol; 2001 Jun; 210(2):96-105. PubMed ID: 11520076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class I-matched allogeneic peripheral blood lymphocytes by B7 gene-modified melanoma cells.
    Yang S; Darrow TL; Seigler HF
    Cancer Res; 1997 Apr; 57(8):1561-8. PubMed ID: 9108460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid expansion of tumor-reactive cells from HLA-matched siblings for adoptive immunotherapy of melanoma.
    Gottlieb DJ; Micklethwaite K; Bradstock KF; Li YC
    Cytotherapy; 2007; 9(2):133-43. PubMed ID: 17453965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
    Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR
    J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effector T cell analysis of melanoma tumor-infiltrating lymphocyte cultures using HLA-ABC semimatched melanoma cell lines.
    Carlsson B; Sadeghi A; Bengtsson M; Wagenius G; Tötterman TH
    J Immunother; 2008 Sep; 31(7):633-43. PubMed ID: 18600181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response.
    Guarini A; Gansbacher B; Cronin K; Fierro MT; Foa R
    Cytokines Mol Ther; 1995 Mar; 1(1):57-64. PubMed ID: 9384664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15.
    Takahashi T; Chapman PB; Yang SY; Hara I; Vijayasaradhi S; Houghton AN
    J Immunol; 1995 Jan; 154(2):772-9. PubMed ID: 7814883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines.
    Dufour E; Carcelain G; Gaudin C; Flament C; Avril MF; Faure F
    J Immunol; 1997 Apr; 158(8):3787-95. PubMed ID: 9103444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TCR beta-chain variable region-driven selection and massive expansion of HLA-class I-restricted antitumor CTL lines from HLA-A*0201+ melanoma patients.
    Maccalli C; Farina C; Sensi M; Parmiani G; Anichini A
    J Immunol; 1997 Jun; 158(12):5902-13. PubMed ID: 9190943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
    Fenton RG; Turcovski-Corrales SM; Taub DD
    J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major histocompatibility complex class I restricted cytotoxic T cells specific for natural melanoma peptides recognize unidentified shared melanoma antigen(s).
    Imro MA; Manici S; Russo V; Consogno G; Bellone M; Rugarli C; Traversari C; Protti MP
    Cancer Res; 1999 May; 59(10):2287-91. PubMed ID: 10344730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of naturally processed and HLA-A1-presented melanoma T-cell epitopes defined by CD8(+) T-cells' release of granulocyte-macrophage colony-stimulating factor but not by cytolysis.
    Maeurer MJ; Martin D; Elder E; Storkus WJ; Lotze MT
    Clin Cancer Res; 1996 Jan; 2(1):87-95. PubMed ID: 9816095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allo-restricted CTLs generated by coculturing of PBLs and autologous monocytes loaded with allogeneic peptide/HLA/IgG1-Fc fusion protein.
    Weng X; Lu S; Zhong M; Liang Z; Shen G; Chen J; Wu X
    J Leukoc Biol; 2009 Mar; 85(3):574-81. PubMed ID: 19112092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.
    Mortarini R; Borri A; Tragni G; Bersani I; Vegetti C; Bajetta E; Pilotti S; Cerundolo V; Anichini A
    Cancer Res; 2000 Jul; 60(13):3559-68. PubMed ID: 10910069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognition and lysis of human melanoma by a CD3+, CD4+, CD8- T-cell clone restricted by HLA-A2.
    Darrow TL; Abdel-Wahab Z; Quinn-Allen MA; Seigler HF
    Cell Immunol; 1996 Aug; 172(1):52-9. PubMed ID: 8806806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
    J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 707-AP peptide recognized by human antibody induces human leukocyte antigen A2-restricted cytotoxic T lymphocyte killing of melanoma.
    Takahashi T; Irie RF; Nishinaka Y; Hoon DS
    Clin Cancer Res; 1997 Aug; 3(8):1363-70. PubMed ID: 9815820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 299.